Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2021 | 3 |
2022 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.
Mult Scler J Exp Transl Clin. 2021 Dec 16;7(4):20552173211066588. doi: 10.1177/20552173211066588. eCollection 2021 Oct.
Mult Scler J Exp Transl Clin. 2021.
PMID: 34950502
Free PMC article.
Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases.
Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR.
Hemond CC, et al. Among authors: kamath v.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211033047. doi: 10.1177/23247096211033047.
J Investig Med High Impact Case Rep. 2021.
PMID: 34308699
Free PMC article.
Item in Clipboard
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR, Kamath A, Button J, Kamath V, Mendoza JP, Zhu B, Plavina T, Woodward C, Penner N.
Edwards KR, et al. Among authors: kamath v.
Mult Scler Relat Disord. 2021 Jun;51:102861. doi: 10.1016/j.msard.2021.102861. Epub 2021 Feb 24.
Mult Scler Relat Disord. 2021.
PMID: 33773271
Item in Clipboard
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.
Jakimovski D, Zakalik K, Awan S, Kavak KS, Pennington P, Hojnacki D, Kolb C, Lizarraga AA, Eckert SP, Sarrosa R, Vineetha K, Edwards K, Weinstock-Guttman B.
Jakimovski D, et al. Among authors: vineetha k.
Vaccines (Basel). 2022 Apr 28;10(5):695. doi: 10.3390/vaccines10050695.
Vaccines (Basel). 2022.
PMID: 35632451
Free PMC article.
Item in Clipboard
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.
Cohan SL, Edwards K, Lucas L, Gervasi-Follmar T, O'Connor J, Siuta J, Kamath V, Garten L, Chen C, Thomas J, Smoot K, Kresa-Reahl K, Spinelli KJ.
Cohan SL, et al. Among authors: kamath v.
Mult Scler J Exp Transl Clin. 2019 Jan 16;5(1):2055217318824618. doi: 10.1177/2055217318824618. eCollection 2019 Jan-Mar.
Mult Scler J Exp Transl Clin. 2019.
PMID: 30729028
Free PMC article.
Item in Clipboard
Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.
Edwards KR, Garten L, Button J, O'Connor J, Kamath V, Frazier C.
Edwards KR, et al. Among authors: kamath v.
Mult Scler Relat Disord. 2019 Jun;31:59-61. doi: 10.1016/j.msard.2019.03.016. Epub 2019 Mar 23.
Mult Scler Relat Disord. 2019.
PMID: 30927733
Item in Clipboard
Cite
Cite